Yuhan Corporation

Jun Kyung Lee

Jong Gyun Kim

Su Youn Nam

Byung Hyun Choi

Hyun Ho Choi

Minji Seo

June Hyung Lee

Ju Young Park

Dohoon Kim

Ki Hong Kim

Soo Yong Chung

Mi Kyeong Ju

Seul Gi Kim

Na Rae Lee

Jun Hwan Kim

Se Woong Oh

Ju-Young Park

Seyoung Lim

Seung Yub Shin

Ho Woong Kang

Su Jin Ahn

The present invention provides a fusion protein comprising an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition comprising the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.

Long-acting FGF21 fusion proteins and pharmaceutical composition comprising same

Provided are a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof, more particularly, a fusion protein comprising a CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection, in which an N-terminal amino acid of a wild-type CCL3&#x3b1; or CCL3&#x3b2; is deleted and an amino acid at a specific position is substituted with a different amino acid at the same position of the wild-type CCL3&#x3b1; or CCL3&#x3b2; in the CCL3 variant.

Fusion protein comprising CCL3 variant and use thereof

Growing community of inventors

Gyeonggi-do, South Korea

Jun Kyung Lee